WEBULL
News
BFRI
0.7063
-4.17%
-0.0307
Weekly Report: what happened at BFRI last week (1215-1219)?
Weekly Report · 2d ago
Biofrontera Transfers Of Ameluz, RhodoLED New Drug Applications, Investigational New Drug Applications; Completes Requirements For Transfer Of All U.S., Some Global Intellectual Property Associated With Ameluz And RhodoLED
Benzinga · 5d ago
Biofrontera completes transfer of Ameluz, RhodoLED FDA approval
TipRanks · 5d ago
Biofrontera Inc. Secures Full Rights to Ameluz and RhodoLED Portfolio
Reuters · 5d ago
BIOFRONTERA INC. COMPLETES TRANSFER OF AMELUZ® AND RHODOLED® FDA APPROVAL AND ASSOCIATED INTELLECTUAL PROPERTY PORTFOLIO
Reuters · 5d ago
Weekly Report: what happened at BFRI last week (1208-1212)?
Weekly Report · 12/15 10:44
Weekly Report: what happened at BFRI last week (1201-1205)?
Weekly Report · 12/08 10:42
Biofrontera completes final patient visit in Phase 1 PK study of Ameluz gel
TipRanks · 12/04 14:15
Biofrontera Completes Final Patient Visit In Phase 1 Pharmacokinetic Study Of Ameluz Gel, 10%, For Treatment Of Mild To Moderate Actinic Keratoses On Neck, Trunk And Extremities
Benzinga · 12/04 14:07
Biofrontera files sNDA for Ameluz-PDT in treatment of sBCC
TipRanks · 12/02 13:50
Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes
Benzinga · 12/02 13:48
BIOFRONTERA INC. ANNOUNCES FILING OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR THE TREATMENT OF SUPERFICIAL BASAL CELL CARCINOMA (SBCC) WITH AMELUZ®-PDT
Reuters · 12/02 13:45
BIOFRONTERA: FILING SEEKS TO EXPAND AMELUZ LABEL TO INCLUDE TREATMENT OF SBCC TREATMENT WITH PDT USING ITS BF-RHODOLED OR RHODOLED XL RED LIGHT LAMPS
Reuters · 12/02 13:45
Weekly Report: what happened at BFRI last week (1124-1128)?
Weekly Report · 12/01 10:36
Biofrontera AG nine-month (9M) EBITDA rises to EUR 1.8 million from a loss, global sales up 14.8 percent to EUR 12.3 million
Reuters · 11/28 09:02
Weekly Report: what happened at BFRI last week (1117-1121)?
Weekly Report · 11/24 10:42
Weekly Report: what happened at BFRI last week (1110-1114)?
Weekly Report · 11/17 10:43
Roth MKM Reaffirms Their Buy Rating on Biofrontera (BFRI)
TipRanks · 11/14 13:57
Biofrontera Inc. Reports Q3 2025 Results and Strategic Moves
TipRanks · 11/14 04:37
Biofrontera, Inc. Navigates Mixed Earnings Call
TipRanks · 11/14 00:45
More
Webull provides a variety of real-time BFRI stock news. You can receive the latest news about Biofrontera Inc through multiple platforms. This information may help you make smarter investment decisions.
About BFRI
Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.